Build for Impact: Fundraising to Stack and Sequence Capital to Fuel Your Medtech Breakthrough

Presenters: Chris Danek, PhD, MBA, CEO, Bessel, and Andres Gutierrez, Program Director, Bessel.

Every medtech founder knows the paradox: investors need data to invest, and founders need funding to create data. In this MTEC session, Chris Danek, a medtech builder with three nine-figure exits and 90+ U.S. patents, walked through Bessel's Build for Impact framework for breaking that loop. The core idea: think like an investor from day one, take risk off the table before raising big money, and sequence the right capital at the right time. Chris also brought a note of optimism from a recent European investor conference, where several seed-stage founders reported lead investors emerging, something that has been hard to come by in recent years.

Who attended: Polling showed roughly 85% of attendees were founders or startup leaders, most at the preclinical or clinical stage, with about half having raised under $1M and half $1M–$5M (including grants).

1. Build for impact: think like an investor
- Pick a problem worth solving. It needs both real clinical impact and a meaningful market. Don't fall in love with a problem until you know it fits investor expectations and your own.
- Define your "guiding lights." Spell out the attributes of the ideal solution: clinical outcomes, workflow, manufacturability. In Chris's atherectomy catheter startup, one deliberately arbitrary constraint (no capital equipment or external suction) became the product's key competitive advantage.
- Plan commercialization now. Clinical need, regulatory and reimbursement check marks are no longer enough. Know who buys and how you get paid. A regulatory path must be clear, though not necessarily short.
- Push "go fast" only when ready. Raise serious money once your concept clearly meets its guiding lights. Pivoting after a raise hurts investors and founders alike.

2. Fundraising is a story of value creation
Value creation and risk reduction are two sides of one coin. Investors weigh a triangle: opportunity size, a differentiated solution, and the right team. Treat your financial model as a living decision tool that breaks your capital strategy into milestone-sized steps. Mind your levels of evidence: "we've done it" beats "our team has done it before," which beats "we'll figure it out." The pitch tells your story; Build for Impact turns it from fiction into nonfiction.

3. Running the process
- It's a sales process. Map each investor's sweet spot (stage, clinical domain, technology), and vet them in return: How much is left in the fund? What exit timelines? Ask their portfolio founders what they're like to work with.
- Lead with a self-expanding elevator pitch. Say who you help, how, and why it's better, and use it everywhere: conversations, LinkedIn, even your email signature. Warm introductions beat cold outreach and "apply through our portal."
- Prepare beyond the deck. Build an overview deck plus white papers that answer the questions you know are coming, along with advisors and fractional support investors can check with.
- Start when almost ready, and be yourself. Get the first "no" out of the way. One investor reported reviewing ~700 decks a week, nearly all of them visibly AI-generated, so the human element stands out.

4. The pitch deck
A pitch is a snapshot in time, not the fundraise. Its job is to capture interest, answer the key questions, and open the door to follow-up. Chris's guidance:
- Answer the four big questions: How big is the opportunity? What is your sustainable advantage? Who will use it, and how will you get paid? Are you the right team?
- Keep it to 12–16 slides, adapted from the Canaan Partners investor pitch workbook, with the team section moved to the middle. Show differentiation twice: in the solution (demo a prototype if you can) and in the competitive landscape.
- Commercialization is the key. Go-to-market, market segmentation and reimbursement deserve dedicated backup material.
- Practice corporate hygiene from day one. A weak design history file or quality system can cut an exit valuation in half.

5. Stack and sequence capital
A typical venture fund lasts about 10 years, but medtech and pharma development often takes longer. Going to venture too early rarely fits. Instead, "ratchet" forward with non-dilutive and dual-use funding (including MTEC), rare disease foundations, and family offices. Avoid paid investor lists and brokers. One Bessel client used paid pilots and foundation investment to reach a seed round and then a Series A.

Q&A highlights
- Tough questions are a gift. Breathe, repeat the question, give a simple top-line answer, then offer a follow-up. Smile and let your points land.
- Keep back-pocket material to email after meetings: financial model detail and precise customer segmentation (your "wedge").
- Network where it's cheap and human. Low-cost clinical and investor meetings, even the lunch line. Show one photo on your phone instead of opening a laptop.

Resources & next steps
- MTEC–QNOVA Life Sciences Partnering Forum during JPM Healthcare Week (January), with Bessel as a platinum sponsor. Includes a seed-stage funding workshop with a dual-use focus, and it's free for startups.
- Bessel Build for Impact Showcase & Reception (JPM week, San Francisco), a relaxed "no-pitch zone."
- Build for Impact Accelerator: applications are open, and MTEC members receive a 20% discount.
- Free 30-minute pitch deck review and action plan: chris@bessel.co.